標題: Titlebook: Advances in Tumor Immunology and Immunotherapy; Joseph D. Rosenblatt,Eckhard R. Podack,Augusto Och Book 2014 Springer Science+Business Med [打印本頁] 作者: Taylor 時間: 2025-3-21 18:20
書目名稱Advances in Tumor Immunology and Immunotherapy影響因子(影響力)
書目名稱Advances in Tumor Immunology and Immunotherapy影響因子(影響力)學(xué)科排名
書目名稱Advances in Tumor Immunology and Immunotherapy網(wǎng)絡(luò)公開度
書目名稱Advances in Tumor Immunology and Immunotherapy網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Advances in Tumor Immunology and Immunotherapy被引頻次
書目名稱Advances in Tumor Immunology and Immunotherapy被引頻次學(xué)科排名
書目名稱Advances in Tumor Immunology and Immunotherapy年度引用
書目名稱Advances in Tumor Immunology and Immunotherapy年度引用學(xué)科排名
書目名稱Advances in Tumor Immunology and Immunotherapy讀者反饋
書目名稱Advances in Tumor Immunology and Immunotherapy讀者反饋學(xué)科排名
作者: 琺瑯 時間: 2025-3-21 20:43 作者: 木質(zhì) 時間: 2025-3-22 03:22 作者: 別名 時間: 2025-3-22 05:08 作者: 枯燥 時間: 2025-3-22 08:44
Induction of Tumor Immunity by Targeted Inhibition of Nonsense-Mediated mRNA Decayty of the tumor provides the time and opportunity for the tumor to elaborate immune evasion mechanisms. Weak antigenicity is, therefore, the root cause why tumors escape immune control. We have recently described a way to activate the antitumor immune response that is fundamentally different from cu作者: 憲法沒有 時間: 2025-3-22 14:02 作者: Obverse 時間: 2025-3-22 20:20 作者: Confound 時間: 2025-3-23 00:17 作者: Choreography 時間: 2025-3-23 05:21 作者: 無聊點好 時間: 2025-3-23 09:07 作者: conduct 時間: 2025-3-23 12:22 作者: 同時發(fā)生 時間: 2025-3-23 16:15 作者: 無所不知 時間: 2025-3-23 21:40 作者: 方便 時間: 2025-3-23 22:30
T Cell Co-regulatory Signals and Their Role in Cancer Therapy can modify this original activating signal. T cell co-regulation is provided by receptors on the T cell surface membrane. Inhibitory signals are provided by CTLA4 or PD-1, while co-stimulation is provided by CD28, 4-1BB, OX40, or GITR. These signals are being studied in the laboratory and at the cl作者: 溫和女人 時間: 2025-3-24 03:22 作者: 沒花的是打擾 時間: 2025-3-24 07:42
https://doi.org/10.1007/978-1-349-11877-9nd some antagonistic, between mechanisms that can impact on the efficacy of therapy. An improved understanding of the relative importance of each mechanism, and how these mechanisms interact in various clinical scenarios, is vital if we are to make a highly valuable approach to cancer therapy even better.作者: 600 時間: 2025-3-24 13:18
Book 2014em. This includes new understanding of T- and B-cell interaction, immune inhibitory mechanisms including the biology of T regulatory cells, myeloid suppressor cells, and dendritic cell subsets. .Enhanced understanding of mechanisms underlying T-cell anergy such as arginine deprivation, immunosuppres作者: Firefly 時間: 2025-3-24 15:28
2199-2584 essive mechanisms, and emerging strategies for manipulation .Recent advances in understanding of fundamental immunology have created new insights into the dynamic interactions between tumors and the immune system. This includes new understanding of T- and B-cell interaction, immune inhibitory mechan作者: ANN 時間: 2025-3-24 20:50
Employing T Cell Homeostasis as an Antitumor Strategyn place for compensatory expansion after depletion, an effect called homeostasis-driven T cell expansion, has been exploited in both preclinical models as well as clinical therapies. This chapter examines both.作者: 閑聊 時間: 2025-3-25 03:10
Activation of NK Cell Responses and Immunotherapy of Cancernd some antagonistic, between mechanisms that can impact on the efficacy of therapy. An improved understanding of the relative importance of each mechanism, and how these mechanisms interact in various clinical scenarios, is vital if we are to make a highly valuable approach to cancer therapy even better.作者: 煉油廠 時間: 2025-3-25 07:16 作者: 起來了 時間: 2025-3-25 08:32
https://doi.org/10.1057/9780230289802ch thus far has prevented determination of an unambiguous phenotype, shared between mice and humans, that has clinical relevance and correlates with their suppressive function. In this chapter we review the current clinical literature on MDSCs in cancer patients, showing that there appear to be two 作者: 吞沒 時間: 2025-3-25 12:27 作者: –LOUS 時間: 2025-3-25 19:06
https://doi.org/10.1057/9780230289802 via the antigen cross-presentation pathway. The enclosed chapter provides a comprehensive overview of heat-shock protein-based cancer vaccines assessed in human clinical trials within the context of parallel progress in understanding the interactions between a developing tumor and the human immune 作者: 落葉劑 時間: 2025-3-25 21:31 作者: Finasteride 時間: 2025-3-26 03:00
Timothy M. Shaw,E. John Inegbedionl as by pre-vaccination of the tumor-bearing mice. Most importantly, we were able to establish a protocol enabling the use of MHC mismatched T-bodies in a safe and effective manner. We found that a single dose of allogeneic T-bodies under mild immunosuppressive conditions could cure metastases, demo作者: Anecdote 時間: 2025-3-26 04:47 作者: Frisky 時間: 2025-3-26 11:38 作者: ACE-inhibitor 時間: 2025-3-26 14:52 作者: Dawdle 時間: 2025-3-26 17:24
Nigeria: A Religious Framing of Grievanceshibitory KIR repertoire of a patient’s NK cells and the affinity of a patient’s Fc receptors for the Fc portion of the mAb molecule. The level of sophistication of antibody-fusion proteins continues to increase with our understanding of patient-intrinsic factors that affect individualized responses 作者: 喪失 時間: 2025-3-26 23:33
https://doi.org/10.1007/978-3-319-51484-0ts of conditioning chemotherapy, multiple strategies to take advantage of the GVT effect that aim to limit morbidity and mortality due to GVHD are under investigation, including cellular therapies employing the use of native or engineered graft populations enriched for antitumor responses, and emplo作者: ascetic 時間: 2025-3-27 04:52 作者: Criteria 時間: 2025-3-27 06:39
Auxiliary Mathematical Results,pression of CTLA4 or PD-1 ligands. Thus manipulation of co-regulatory signals can be used as a strategy by which to strengthen the immune response, via augmentation of T cell co-stimulation and/or blockade of inhibitory signals, in order to effectively treat cancer. In this chapter we review the bas作者: DEBT 時間: 2025-3-27 09:50
Interaction of Group of Controlled Objects,d alterations in immune responses and clinical endpoints, is finally being achieved, and potential immune biomarkers of disease-free or overall survival are being identified. In most cases, validation of these immune biomarkers remains to be performed. There is hope that reliable immune biomarkers o作者: Encapsulate 時間: 2025-3-27 17:38
Myeloid-Derived Suppressor Cells in Cancerch thus far has prevented determination of an unambiguous phenotype, shared between mice and humans, that has clinical relevance and correlates with their suppressive function. In this chapter we review the current clinical literature on MDSCs in cancer patients, showing that there appear to be two 作者: insolence 時間: 2025-3-27 21:02
The Role of B Cells in Shaping the Antitumor Immune Responseisms have been implicated in B cell-mediated suppression of antitumor immunity including (1) preferential polarization of immune responses to Th2; (2) direct suppression of tumor immunity by immunosuppressive regulatory B cells (Breg), and (3) coordination of regulatory T cell (Treg) recruitment and作者: 冬眠 時間: 2025-3-28 00:00 作者: 喊叫 時間: 2025-3-28 03:54 作者: lipoatrophy 時間: 2025-3-28 07:13
Adoptive Cell Therapy of Systemic Metastases Using erbB-2-Specific T Cells Redirected with a Chimeril as by pre-vaccination of the tumor-bearing mice. Most importantly, we were able to establish a protocol enabling the use of MHC mismatched T-bodies in a safe and effective manner. We found that a single dose of allogeneic T-bodies under mild immunosuppressive conditions could cure metastases, demo作者: Ceremony 時間: 2025-3-28 14:24
Immunotherapy in Renal Cell Carcinoma I trials. Peptide vaccines have shown efficacy in phase II trials as well. Phase III trials to test these immune interventions are currently ongoing and have the potential to bring new, effective treatment options for patients with advanced RCC.作者: notification 時間: 2025-3-28 15:58 作者: GIDDY 時間: 2025-3-28 22:48 作者: intrigue 時間: 2025-3-28 22:57 作者: 腐敗 時間: 2025-3-29 04:51 作者: Chandelier 時間: 2025-3-29 10:26
The Immune System in Head and Neck Squamous Cell Carcinoma: Interactions and Therapeutic Opportunitiparent that efforts to stimulate a therapeutically effective immune response against established tumors must be coupled with strategies to abrogate this immune-suppressive environment. Preclinical studies and clinical trials have yielded promising results and provide the foundation for further refin作者: 狂亂 時間: 2025-3-29 14:42
T Cell Co-regulatory Signals and Their Role in Cancer Therapypression of CTLA4 or PD-1 ligands. Thus manipulation of co-regulatory signals can be used as a strategy by which to strengthen the immune response, via augmentation of T cell co-stimulation and/or blockade of inhibitory signals, in order to effectively treat cancer. In this chapter we review the bas作者: 急急忙忙 時間: 2025-3-29 15:51 作者: 尖牙 時間: 2025-3-29 20:05 作者: 他一致 時間: 2025-3-30 01:50
2199-2584 these strategies have already been realized in the clinic. The volume will explore evolving paradigms in antigen presentation, dendritic cell biology, the innate response and immunosuppressive mechanisms, and 978-1-4939-5097-3978-1-4614-8809-5Series ISSN 2199-2584 Series E-ISSN 2199-2592 作者: 考博 時間: 2025-3-30 05:54
https://doi.org/10.1057/9780230289802 cells and cytokines, which not only inhibit the host’s antitumor immune response, but also hinder the clinical efficacy of immune-based therapies. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous collection of immature myeloid cells that play an important role in cancer immune eva作者: 反復(fù)拉緊 時間: 2025-3-30 11:26
https://doi.org/10.1057/9780230289802s known about the role of B cells in tumor immunity. The ability and mechanism of B cell-mediated regulation of cellular immune responses and inflammation have only recently been described and remain incompletely understood. Although B cells are recognized as a significant proportion of tumor-infilt作者: 思考才皺眉 時間: 2025-3-30 14:54 作者: 流行 時間: 2025-3-30 20:07 作者: Armory 時間: 2025-3-30 22:35
International Political Economy Seriesty of the tumor provides the time and opportunity for the tumor to elaborate immune evasion mechanisms. Weak antigenicity is, therefore, the root cause why tumors escape immune control. We have recently described a way to activate the antitumor immune response that is fundamentally different from cu作者: 周年紀念日 時間: 2025-3-31 03:49 作者: 物種起源 時間: 2025-3-31 07:48 作者: neoplasm 時間: 2025-3-31 12:09
Iraq and Syria: Complex, Dynamic and Divided. The observation that RCC is immunogenic led to immune-based strategies for the treatment of this disease. Immunotherapy with high-dose IL-2 can induce long-term, complete responses in a small percentage of patients. IFN has been used as an immune intervention as well but with much less success tha
